Oncoinvent AS
Kjelsavn. 168B
Oslo
0884
Tel: 47-22-18-33-05
Website: http://www.oncoinvent.com/
Email: oncoinvent@oncoinvent.com
About Oncoinvent AS
Oncoinvent AS is developing therapeutics to combat various cancers. Immunotargeting of tumor cells and/or delivery of tumour-cell killing doses of radiation are the main mechanisms of the products of Oncoinvent AS.YEAR FOUNDED:
2010
LEADERSHIP:
Founder and CSO: Tina Bjørnlund Bønsdorff
CEO: Jan Alan Alfheim
CMO: Øyvind Sverre Bruland
CFO: Ole Peter Nordby
CLINICAL TRIAL:
Please click here for clinical trial information.
PRODUCTS:
Radspherin
15 articles about Oncoinvent AS
-
Oncoinvent Presents Preliminary 18-Month Safety and Efficacy Data from Ongoing RAD-18-002 Phase 1/2A Trial of Radspherin® in Colorectal Cancer Patients at the 13th PSOGI International Congress on Peritoneal Surface Malignancies
10/4/2023
Oncoinvent AS announced the presentation of preliminary 18-month safety and efficacy data from its ongoing Phase 1/2A clinical trial evaluating the safety, tolerability, and signal of efficacy of Radspherin® in patients with peritoneal carcinomatosis from colorectal cancer at the 13th International Congress on Peritoneal Surface Malignancies of the Peritoneal Surface Oncology Group International, to be held at the Palazzo del Cinema in Venice, Italy from October 4 - 6, 2023.
-
Oncoinvent To Present Initial Safety Data from the Phase 1 Trial of Radspherin® in Ovarian Cancer Patients at the 24th Congress of the European Society of Gynaecological Oncology (ESGO)
9/28/2023
Oncoinvent AS today announced the presentation of initial safety data from the ongoing Phase 1 clinical trial evaluating the recommended dose, safety and tolerability of Radspherin® in patients with recurrent ovarian cancer at the 24th Congress of the European Society of Gynaecological Oncology (ESGO) being held at the Istanbul Congress Center in Istanbul, Türkiye from September 28 – October 1, 2023.
-
Oncoinvent appoints Anders Månsson as CEO
7/5/2023
Oncoinvent AS today announced the appointment of Anders Månsson as Chief Executive Officer (CEO), effective September 1st , 2023.
-
Oncoinvent Announces Two Publications in Special Edition of Frontiers in Medicine Focused on Alpha Radioisotopes
4/21/2023
Oncoinvent Announces Two Publications in Special Edition of Frontiers in Medicine Focused on Alpha Radioisotopes.
-
Oncoinvent Initiates Radspherin® Phase 2A Trial
8/25/2022
Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of cancers, announced that the first colorectal cancer patient in the RAD-18-002 phase 2A clinical trial has been treated with its drug candidate, Radspherin®.
-
Data From the Ongoing Radspherin® RAD-18-002 Phase 1 Trial in Colorectal Cancer Patients to Be Presented at the 2022 ASCO Annual Meeting
5/26/2022
Oncoinvent AS, a clinical stage company advancing a pipeline of radiopharmaceutical products across a variety of solid cancers, today announced that interim safety data from its ongoing Phase 1 RAD-18-002 clinical trial assessing the dose, safety, and tolerability of Radspherin®, in patients with peritoneal carcinomatosis from colorectal carcinoma will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
-
Oncoinvent to Present at Guggenheim Radiopharmaceuticals Day
5/10/2022
Oncoinvent AS announced that members of management will present at the Guggenheim Radiopharmaceuticals Day on Tuesday, May 17, 2022 in New York, NY.
-
Oncoinvent to Participate in Upcoming Virtual Investor Conferences - Feb 15, 2022
2/15/2022
Oncoinvent AS, a clinical stage company advancing a pipeline of radiopharmaceutical products across a variety of solid cancers, announced that members of management will participate in two upcoming virtual investor conferences.
-
Oncoinvent appoints Adrian Senderowicz MD to its Board of Directors
2/4/2022
Oncoinvent AS announces that Adrian Senderowicz was elected as a Non-executive Director today at the Company's Extraordinary General Meeting.
-
Oncoinvent Announces Completion of Enrollment in the RAD-18-002 Phase 1 Clinical Study
11/8/2021
Oncoinvent AS, a clinical stage company advancing a pipeline of radiopharmaceutical products across a variety of solid cancers, announced that it has successfully completed recruitment of the Radspherin® RAD-18-002 clinical study.
-
Oncoinvent to Present Four Posters at the 34th Annual Congress of the European Association of Nuclear Medicine
10/20/2021
Oncoinvent to Present Four Posters at the 34th Annual Congress of the European Association of Nuclear Medicine
-
Oncoinvent Strengthens Leadership Team - Oct 04, 2021
10/4/2021
Oncoinvent AS announced that it has appointed Dr. Kari Myren, MD to the role of Chief Medical Officer, Dr. Anne-Kirsti Aksnes to the role of Vice President Clinical Operations, and Mr. Stian Brekke to the role of Head of Regulatory Affairs.
-
Oncoinvent Announces Advancement of Radspherin® to Fourth Dose Level Cohort in Ongoing RAD-18-001 Phase 1 Trial in Ovarian Cancer Patients
9/28/2021
Oncoinvent Announces Advancement of Radspherin ® to Fourth Dose Level Cohort in Ongoing RAD-18-001 Phase 1 Trial in Ovarian Cancer Patients
-
Following a Year of Outstanding Performance, Oncoinvent Aims to Raise NOK 150-200 Million to Move Into Efficacy Studies With Radspherin®
6/23/2021
Oncoinvent AS, a clinical stage company advancing a pipeline of radiopharmaceutical products across a variety of solid cancers, announced plans to raise a private round of financing.
-
Oncoinvent AS Patent Issues In The USA
1/18/2017